SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/E421412B7001620370EC118D7AD6D0BE99801F4D36012DDD5B803A7D48CCC1CED1F7FDF4BC58F25DED2BE69D34CAAD60>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/E421412B7001620370EC118D7AD6D0BE99801F4D36012DDD5B803A7D48CCC1CED1F7FDF4BC58F25DED2BE69D34CAAD60
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/E421412B7001620370EC118D7AD6D0BE99801F4D36012DDD5B803A7D48CCC1CED1F7FDF4BC58F25DED2BE69D34CAAD60
http://www.w3.org/2000/01/rdf-schema#comment
"These results suggest that eltrombopag can partially modulate some immune responses by TGFbeta(1) and sCTLA-4 but it does not induce immune tolerance by 24 weeks after treatment."
xsd:string
http://purl.uniprot.org/uniprot/#_D387A9397CA80F8C1799C857956F41B729EE2F2D46BC519B1CCE50927C8FCAA1080AE007E4A01395063890D79AA06C69
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/E421412B7001620370EC118D7AD6D0BE99801F4D36012DDD5B803A7D48CCC1CED1F7FDF4BC58F25DED2BE69D34CAAD60
http://purl.uniprot.org/uniprot/A0A140VJH4
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/E421412B7001620370EC118D7AD6D0BE99801F4D36012DDD5B803A7D48CCC1CED1F7FDF4BC58F25DED2BE69D34CAAD60
http://purl.uniprot.org/uniprot/#_A0A140VJH4-mappedCitation-22789125
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/E421412B7001620370EC118D7AD6D0BE99801F4D36012DDD5B803A7D48CCC1CED1F7FDF4BC58F25DED2BE69D34CAAD60